cancer of unknown primary

The prize was established in 2013 to help fund explorative and high-risk/high-reward cancer research in areas where traditional funding is often lacking.

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.

N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.

The state of California has given the lab permission to start offering its QClamp test to screen for tumor oncogenic driver and resistance mutations in tumor DNA.

The partners will investigate whether RareCyte's technology can be used to analyze immune cell populations and CTCs in samples from NCI studies.

Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.

They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.

Their clinical trial will compare the effectiveness of tissue biopsies and liquid biopsies for tumor detection and monitoring.

The financing round has an option for an additional $10 million investment.